CONMED Corporation (NASDAQ:CNMD) Director Jo Ann Golden sold 3,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now directly owns 19,782 shares of the company’s stock, valued at $989,100. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CONMED Corporation (NASDAQ CNMD) traded down 0.38% during midday trading on Tuesday, hitting $49.95. 59,249 shares of the company were exchanged. The firm’s 50-day moving average price is $50.32 and its 200-day moving average price is $47.39. The stock has a market capitalization of $1.39 billion, a PE ratio of 89.36 and a beta of 0.67. CONMED Corporation has a one year low of $37.60 and a one year high of $52.82.

CONMED Corporation (NASDAQ:CNMD) last posted its earnings results on Wednesday, July 26th. The medical technology company reported $0.41 EPS for the quarter, hitting the consensus estimate of $0.41. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. The business had revenue of $197.20 million for the quarter, compared to the consensus estimate of $194.50 million. During the same period last year, the company earned $0.47 EPS. The firm’s revenue was up 2.0% compared to the same quarter last year. Equities research analysts anticipate that CONMED Corporation will post $1.87 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/15/insider-selling-conmed-corporation-cnmd-director-sells-3000-shares-of-stock.html.

Large investors have recently bought and sold shares of the company. State of Alaska Department of Revenue increased its stake in CONMED Corporation by 1.9% in the first quarter. State of Alaska Department of Revenue now owns 2,730 shares of the medical technology company’s stock valued at $121,000 after buying an additional 50 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in CONMED Corporation by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 10,100 shares of the medical technology company’s stock valued at $449,000 after buying an additional 100 shares in the last quarter. Rothschild Asset Management Inc. increased its stake in CONMED Corporation by 0.3% in the second quarter. Rothschild Asset Management Inc. now owns 35,232 shares of the medical technology company’s stock valued at $1,795,000 after buying an additional 107 shares in the last quarter. Texas Permanent School Fund increased its stake in CONMED Corporation by 1.0% in the second quarter. Texas Permanent School Fund now owns 18,111 shares of the medical technology company’s stock valued at $923,000 after buying an additional 173 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in CONMED Corporation by 1.6% in the first quarter. Arizona State Retirement System now owns 12,903 shares of the medical technology company’s stock valued at $573,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

A number of equities analysts have weighed in on CNMD shares. BidaskClub downgraded shares of CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Zacks Investment Research downgraded shares of CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Needham & Company LLC boosted their price target on shares of CONMED Corporation from $48.00 to $54.00 and gave the stock a “buy” rating in a research note on Thursday, April 27th. Ladenburg Thalmann Financial Services downgraded shares of CONMED Corporation from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $50.00 to $48.00 in a research note on Thursday, April 27th. Finally, TheStreet raised shares of CONMED Corporation from a “c+” rating to a “b-” rating in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. CONMED Corporation presently has an average rating of “Hold” and an average price target of $49.33.

CONMED Corporation Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Insider Buying and Selling by Quarter for CONMED Corporation (NASDAQ:CNMD)

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.